12月24日，澳华内镜跌0.04%，成交额5805.17万元。两融数据显示，当日澳华内镜获融资买入额510.35 万元，融资偿还772.22万元，融资净买入-261.88万元。截至12月24日，澳华内镜融资融券余额合计1.25 亿元。 机构持仓方面，截止2025年9月30日，澳华内镜十大流通股东中，富国精准医疗灵活配置混合A （005176）位居第三大流通股东，持股534.06万股，相比上期增加50.55万股。汇添富创新医药混合A （006113）位居第五大流通股东，持股358.52万股，相比上期减少31.33万股。汇添富医疗服务灵活配置 混合A（001417）位居第八大流通股东，持股204.51万股，相比上期减少24.36万股。工银前沿医疗股票 A（001717）、广发医疗保健股票A（004851）退出十大流通股东之列。 融资方面，澳华内镜当日融资买入510.35万元。当前融资余额1.25亿元，占流通市值的2.07%，融资余 额超过近一年80%分位水平，处于高位。 责任编辑：小浪快报 截至9月30日，澳华内镜股东户数5549.00，较上期增加41.52%；人均流通股24268股，较上期减少 29.34%。2 ...

12月23日，澳华内镜跌3.21%，成交额6916.41万元。两融数据显示，当日澳华内镜获融资买入额863.97 万元，融资偿还329.39万元，融资净买入534.58万元。截至12月23日，澳华内镜融资融券余额合计1.28 亿元。 分红方面，澳华内镜A股上市后累计派现7628.41万元。近三年，累计派现5094.95万元。 融资方面，澳华内镜当日融资买入863.97万元。当前融资余额1.28亿元，占流通市值的2.11%，融资余 额超过近一年80%分位水平，处于高位。 机构持仓方面，截止2025年9月30日，澳华内镜十大流通股东中，富国精准医疗灵活配置混合A （005176）位居第三大流通股东，持股534.06万股，相比上期增加50.55万股。汇添富创新医药混合A （006113）位居第五大流通股东，持股358.52万股，相比上期减少31.33万股。汇添富医疗服务灵活配置 混合A（001417）位居第八大流通股东，持股204.51万股，相比上期减少24.36万股。工银前沿医疗股票 A（001717）、广发医疗保健股票A（004851）退出十大流通股东之列。 融券方面，澳华内镜12月23日融券偿还0.00股，融 ...

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a significant increase in its stock price, rising by 5.42% to 49.39 CNY per share, with a total market capitalization of 6.651 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, is a high-tech enterprise located in Shanghai, primarily engaged in the research, production, and sales of electronic endoscopy equipment and related medical consumables [1] - The company's main revenue sources are: endoscopy equipment (92.35%), endoscopy diagnostic consumables (3.71%), endoscopy maintenance services (3.58%), and leasing income (0.35%) [1] Group 2 - According to data, Aohua Endoscopy is a top ten holding in the Agricultural Bank of China Fund's Aohua Specialized and New Mixed Fund (016305), which increased its holdings by 2,831 shares in the third quarter, now holding 57,300 shares, representing 2.32% of the fund's net value [2] - The Aohua Specialized and New Mixed Fund has achieved a year-to-date return of 47.01%, ranking 1,341 out of 8,148 in its category, and a one-year return of 37.65%, ranking 1,639 out of 8,053 [2] - The fund manager, Wei Gang, has been in position for 7 years and 229 days, with the fund's total asset size at 540 million CNY and a best return of 131.83% during his tenure [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a stock price increase of 5.1%, reaching 51.73 yuan per share, with a total market capitalization of 6.966 billion yuan [1] - Aohua Endoscopy, established on October 27, 1994, specializes in the research, production, and sales of electronic endoscope equipment and related medical consumables, with 92.35% of its revenue coming from endoscope equipment [1] - The company is classified as a high-tech enterprise, with additional revenue sources including endoscope consumables (3.71%), maintenance services (3.58%), and leasing (0.35%) [1] Group 2 - Xiangcai Fund has a significant holding in Aohua Endoscopy, with its Xiangcai Medical Health Mixed A fund holding 18,000 shares, representing 4.8% of the fund's net value [2] - The fund has achieved a year-to-date return of 44.3%, ranking 1642 out of 8155 in its category, and a one-year return of 36.51%, ranking 2016 out of 8029 [2] - The fund manager, Zhang Quan, has been in position for 1 year and 308 days, with the fund's total assets amounting to 18.3775 million yuan [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a stock price increase of 5.3%, reaching 50.86 CNY per share, with a total market capitalization of 6.849 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, specializes in the research, production, and sales of electronic endoscope equipment and related medical consumables, with 92.35% of its revenue coming from endoscope equipment [1] - The company is located in Minhang District, Shanghai, and was listed on November 15, 2021 [1] Group 2 - Among the top ten circulating shareholders of Aohua Endoscopy, one fund from GF Fund Management, the GF Healthcare Stock A (004851), has entered the list, holding 1.7267 million shares, which is 1.28% of the circulating shares [2] - The GF Healthcare Stock A fund was established on August 10, 2017, and has a current scale of 5.247 billion CNY, with a year-to-date return of 19.8% [2] - The fund's performance ranks 2665 out of 4218 in its category this year, and it has achieved a cumulative return of 93.64% since inception [2] Group 3 - The fund manager of GF Healthcare Stock A is Wu Xingwu, who has been in the position for 10 years and 258 days, managing assets totaling 9.853 billion CNY [3] - During his tenure, the best fund return achieved was 105.25%, while the worst return was -37.23% [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy has seen a significant increase in its stock price, rising by 5.45% to 49.88 CNY per share, with a total market capitalization of 6.717 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, is a high-tech enterprise located in Shanghai, primarily engaged in the research, production, and sales of electronic endoscopy equipment and related medical consumables [1] - The company's main revenue sources are: endoscopy equipment (92.35%), endoscopy consumables (3.71%), endoscopy maintenance services (3.58%), and leasing income (0.35%) [1] Group 2 - Aohua Endoscopy is a significant holding in the fund managed by Agricultural Bank of China, with the Aohua Endoscopy stock representing 2.58% of the fund's net value, making it the fifth-largest holding [2] - The Agricultural Bank of China fund, named Agricultural Bank of China Specialized and New Mixed A (016305), has achieved a year-to-date return of 39.95% and ranks 1392 out of 8162 in its category [2] - The fund manager, Wei Gang, has been in charge for over 7 years, with the best fund return during his tenure being 121.47% [3]

Group 1 - The core viewpoint of the news is that Aohua Endoscopy experienced a stock price increase of 5.45%, reaching 49.88 CNY per share, with a total market capitalization of 6.717 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, is a high-tech enterprise located in Shanghai, primarily engaged in the research, production, and sales of electronic endoscopy equipment and related medical consumables [1] - The revenue composition of Aohua Endoscopy includes 92.35% from endoscopy equipment, 3.71% from endoscopic diagnostic consumables, 3.58% from maintenance services, and 0.35% from leasing [1] Group 2 - Among the top ten circulating shareholders of Aohua Endoscopy, ICBC Credit Suisse Fund's Aohua Medical Stock A (001717) reduced its holdings by 805,800 shares, now holding 3.0942 million shares, which is 2.3% of the circulating shares [2] - The Aohua Medical Stock A fund has achieved a year-to-date return of 26.76% and a one-year return of 20.01%, ranking 1686 out of 4218 and 2253 out of 3868 in its category, respectively [2] - The fund manager, Zhao Bei, has been in position for 10 years and 341 days, with the fund's total asset size at 16.425 billion CNY and a best return of 233% during his tenure [3]

Group 1 - The stock price of Aohua Endoscopy has declined by 1.57% to 46.25 CNY per share, with a total market capitalization of 6.228 billion CNY, and a cumulative drop of 9.46% over the last four days [1] - Aohua Endoscopy, established on October 27, 1994, specializes in the research, production, and sales of electronic endoscope equipment and related medical consumables, with 92.35% of its revenue coming from endoscope equipment [1] Group 2 - Beixin Ruifeng Fund holds 100,000 shares of Aohua Endoscopy in its health lifestyle theme flexible allocation fund, representing 5.48% of the fund's net value, with a floating loss of approximately 74,000 CNY today and 483,000 CNY over the four-day decline [2] - The Beixin Ruifeng Health Lifestyle Theme Flexible Allocation Fund (001056) has a total scale of 90.1431 million CNY and has achieved a year-to-date return of 29.83% [2]

Group 1 - The core point of the news is that Aohua Endoscopy experienced a decline of 5.01% in its stock price, reaching 48.52 CNY per share, with a total market capitalization of 6.534 billion CNY [1] - Aohua Endoscopy, established on October 27, 1994, is a high-tech enterprise based in Shanghai, primarily engaged in the research, production, and sales of electronic endoscopy equipment and related medical consumables [1] - The company's revenue composition includes 92.35% from endoscopy equipment, 3.71% from endoscopic diagnostic consumables, 3.58% from endoscopy maintenance services, and 0.35% from leasing [1] Group 2 - According to data, a fund under Southern Fund holds Aohua Endoscopy as its tenth largest position, with 1.3553 million shares, accounting for 2.75% of the fund's net value [2] - The Southern Medical Health Flexible Allocation Mixed A Fund (000452) has reported a floating loss of approximately 3.4696 million CNY today [2] - The fund has a total scale of 2.405 billion CNY and has achieved a year-to-date return of 45.98%, ranking 1334 out of 8162 in its category [2]

Core Viewpoint - Aohua Endoscopy experienced a decline in stock price and significant net selling in margin trading on September 25, indicating potential investor concerns about the company's financial performance and market position [1]. Financial Performance - For the first half of 2025, Aohua Endoscopy reported revenue of 260 million yuan, a year-on-year decrease of 26.36% [2]. - The company recorded a net loss attributable to shareholders of 40.77 million yuan, representing a substantial decline of 820.03% compared to the previous period [2]. Shareholder and Market Activity - As of June 30, 2025, the number of shareholders decreased by 2.51% to 3,921, while the average number of circulating shares per person increased by 2.58% to 34,344 shares [2]. - On September 25, the financing buy-in amount was 5.19 million yuan, while the financing repayment was 10.47 million yuan, resulting in a net financing outflow of 5.28 million yuan [1]. - The total margin trading balance for Aohua Endoscopy reached 107 million yuan, accounting for 1.66% of its market capitalization, indicating a high level of margin trading activity [1]. Dividend and Institutional Holdings - Aohua Endoscopy has distributed a total of 76.28 million yuan in dividends since its A-share listing, with 50.95 million yuan distributed over the past three years [3]. - Among the top ten circulating shareholders as of June 30, 2025, notable changes include an increase in holdings by the third-largest shareholder and new entries from two funds, indicating shifting institutional interest [3].